ResMed (RMD) : Hunter Associates Investment Management reduced its stake in ResMed by 0.44% during the most recent quarter end. The investment management company now holds a total of 83,330 shares of ResMed which is valued at $4.8 Million after selling 365 shares in ResMed , the firm said in a disclosure report filed with the SEC on May 13, 2016.ResMed makes up approximately 2.20% of Hunter Associates Investment Management’s portfolio.
Other Hedge Funds, Including , Van Eck Associates Corp boosted its stake in RMD in the latest quarter, The investment management firm added 165 additional shares and now holds a total of 1,057 shares of ResMed which is valued at $60,714.Morgan Dempsey Capital Management reduced its stake in RMD by selling 148 shares or 6.33% in the most recent quarter. The Hedge Fund company now holds 2,190 shares of RMD which is valued at $125,794. ResMed makes up approx 0.05% of Morgan Dempsey Capital Management’s portfolio.Tiaa Cref Investment Management boosted its stake in RMD in the latest quarter, The investment management firm added 47,437 additional shares and now holds a total of 485,917 shares of ResMed which is valued at $27.4 Million. ResMed makes up approx 0.02% of Tiaa Cref Investment Management’s portfolio.Pacad Investment Ltd. boosted its stake in RMD in the latest quarter, The investment management firm added 18,944 additional shares and now holds a total of 26,744 shares of ResMed which is valued at $1.5 Million. ResMed makes up approx 0.17% of Pacad Investment Ltd.’s portfolio.California Public Employees Retirement System boosted its stake in RMD in the latest quarter, The investment management firm added 33,600 additional shares and now holds a total of 387,600 shares of ResMed which is valued at $21.9 Million. ResMed makes up approx 0.03% of California Public Employees Retirement System’s portfolio.
ResMed closed down -0.41 points or -0.71% at $57.72 with 9,40,328 shares getting traded on Wednesday. Post opening the session at $58.39, the shares hit an intraday low of $57.72 and an intraday high of $58.53 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, ResMed reported $0.68 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.69. The company had revenue of $453.88 million for the quarter, compared to analysts expectations of $455.94 million. The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.65 EPS.
Many Wall Street Analysts have commented on ResMed. ResMed was Upgraded by Macquarie to ” Neutral” on Apr 28, 2016. ResMed was Downgraded by Piper Jaffray to ” Neutral” on Apr 27, 2016. Barclays Resumed ResMed on Apr 7, 2016 to “Underweight”, Price Target of the shares are set at $55.
ResMed Inc. is engaged in the development manufacturing distribution and marketing of medical products for the diagnosis treatment and management of respiratory disorders with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders including airflow generators diagnostic products mask systems headgear and other accessories. It produces continuous positive airway pressure variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape AirSense 10 Elite AirSense 10 CPAP S9 VPAP S S9 VPAP ST S9 VPAP Adapt S9 VPAP ST-A S9 VPAP COPD and AirCurve 10 V Auto among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX Swift FX for Her Mirage FX for Her Pixi Pediatric Mask Quattro FX for Her Swift FX Bella Swift FX Nano AirFit N10 and Apnealink Air.